Nuvation Bio Inc. Class A Common Stock (NUVB)

Boston, MA – November 19, 2025 – Nuvation Bio Inc. (NASDAQ: NUVB) has captured the financial spotlight, witnessing a remarkable 47.71% surge in its stock price following a stellar third-quarter 2025 earnings report. The biopharmaceutical company not only significantly surpassed revenue forecasts but also celebrated the highly successful commercial launch of

Looking for insights into the US markets one hour before the close of the markets on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Looking for insights into the US markets in the middle of the day on Wednesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.

Nuvation Bio (NUVB) Q3 2025 Earnings Transcript

Nuvation Bio Chief Scientist Sells 100,000 Shares Under Trading Plan — Here's What to Know About the Stock

The bulls are lining up on Wall Street for this up-and-coming biotech stock.

Nuvation Bio (NUVB) reported Q2 2025 results with a massive revenue beat ($4.83M vs. $364K est.) driven by IBTROZI launch, but EPS met expectations (-$0.17). Cash at $607.7M, pipeline progressing.

FDA approves Ibtrozi for ROS1+ non-small cell lung cancer based on data from over 300 patients in two pivotal trials showing high response rates.

Nuvation Bio halts its NUV-868 BET inhibitor program after Phase 1 study analysis. The decision impacts solid tumor treatments in ovarian, pancreatic, and mCRPC cancers, focusing instead on late-stage pipeline developments.